KR20180004233A - 상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 - Google Patents
상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 Download PDFInfo
- Publication number
- KR20180004233A KR20180004233A KR1020177035145A KR20177035145A KR20180004233A KR 20180004233 A KR20180004233 A KR 20180004233A KR 1020177035145 A KR1020177035145 A KR 1020177035145A KR 20177035145 A KR20177035145 A KR 20177035145A KR 20180004233 A KR20180004233 A KR 20180004233A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- starch
- poly
- microparticles
- polyinosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002472 Starch Polymers 0.000 title claims abstract description 136
- 235000019698 starch Nutrition 0.000 title claims abstract description 134
- 239000008107 starch Substances 0.000 title claims abstract description 130
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 238000009472 formulation Methods 0.000 title description 13
- 239000011859 microparticle Substances 0.000 claims abstract description 80
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims abstract description 42
- 208000015181 infectious disease Diseases 0.000 claims abstract description 32
- 230000009385 viral infection Effects 0.000 claims abstract description 28
- 208000036142 Viral infection Diseases 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 8
- 229930183912 Cytidylic acid Natural products 0.000 claims abstract 3
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 206010061494 Rhinovirus infection Diseases 0.000 claims description 3
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000856 Amylose Polymers 0.000 description 23
- 108090000467 Interferon-beta Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 229920000945 Amylopectin Polymers 0.000 description 15
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 13
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 229920002261 Corn starch Polymers 0.000 description 12
- 102000003996 Interferon-beta Human genes 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 239000008120 corn starch Substances 0.000 description 12
- 229960001388 interferon-beta Drugs 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 241000709661 Enterovirus Species 0.000 description 8
- -1 nucleoside phosphate Chemical class 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 102100026720 Interferon beta Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 241000709664 Picornaviridae Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
- 241000254158 Lampyridae Species 0.000 description 4
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000001341 hydroxy propyl starch Substances 0.000 description 4
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 102000007863 pattern recognition receptors Human genes 0.000 description 4
- 108010089193 pattern recognition receptors Proteins 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229940050526 hydroxyethylstarch Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000013541 low molecular weight contaminant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- NMUKKQFFBNEVJY-UHFFFAOYSA-K 4-O-bis[(4-oct-1-enoxy-4-oxobutanoyl)oxy]alumanyl 1-O-oct-1-enyl butanedioate Chemical compound [Al+3].CCCCCCC=COC(=O)CCC([O-])=O.CCCCCCC=COC(=O)CCC([O-])=O.CCCCCCC=COC(=O)CCC([O-])=O NMUKKQFFBNEVJY-UHFFFAOYSA-K 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920001685 Amylomaize Polymers 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 239000004370 Bleached starch Substances 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000219729 Lathyrus Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047473 Viral pharyngitis Diseases 0.000 description 1
- 239000001073 acetylated oxidized starch Substances 0.000 description 1
- 235000013770 acetylated oxidized starch Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019428 bleached starch Nutrition 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- 125000002740 cytidyl group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013826 starch sodium octenyl succinate Nutrition 0.000 description 1
- 239000001334 starch sodium octenyl succinate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000010947 wet-dispersion method Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
- C08L3/02—Starch; Degradation products thereof, e.g. dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167129 | 2015-05-11 | ||
| EP15167129.4 | 2015-05-11 | ||
| PCT/IB2016/000890 WO2016181226A1 (en) | 2015-05-11 | 2016-05-10 | Polyinosinic-polycytidylic acid (poly(i:c)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180004233A true KR20180004233A (ko) | 2018-01-10 |
Family
ID=53174864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177035145A Withdrawn KR20180004233A (ko) | 2015-05-11 | 2016-05-10 | 상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180353533A1 (enExample) |
| EP (1) | EP3294268A1 (enExample) |
| JP (1) | JP2018515530A (enExample) |
| KR (1) | KR20180004233A (enExample) |
| CN (1) | CN107820423A (enExample) |
| AU (1) | AU2016259869A1 (enExample) |
| CA (1) | CA2983659A1 (enExample) |
| HK (1) | HK1251926A1 (enExample) |
| MA (1) | MA44384A (enExample) |
| RU (1) | RU2017142710A (enExample) |
| TW (1) | TW201705963A (enExample) |
| WO (1) | WO2016181226A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102439760B1 (ko) | 2021-03-09 | 2022-09-02 | 주식회사 오라팜 | 상기도 감염균 질환 예방 및 치료를 위한 조성물 |
| KR20220126619A (ko) | 2021-03-09 | 2022-09-16 | 주식회사 오라팜 | 급성 호흡기 바이러스 및 로타바이러스 감염 질환 예방 및 치료를 위한 조성물 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112423771B (zh) * | 2018-07-20 | 2023-05-09 | 株式会社资生堂 | 病毒灭活剂 |
| CU20200110A7 (es) * | 2020-12-23 | 2022-08-09 | Ct Ingenieria Genetica Biotecnologia | Péptidos para el tratamiento de infecciones respiratorias de origen viral |
| CN114917242A (zh) * | 2022-05-31 | 2022-08-19 | 复旦大学附属中山医院 | 合成双链rna类似物经滴鼻预防呼吸道传播病毒的应用及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| CN101229378A (zh) * | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
| JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
| CN101757018A (zh) * | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
| CN102988303A (zh) * | 2011-09-15 | 2013-03-27 | 天津泽世德生物医药有限公司 | 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法 |
| US9682096B2 (en) * | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| TWI643082B (zh) * | 2013-09-03 | 2018-12-01 | 美商新思科技股份有限公司 | 一種佈線出一解決路徑之方法及系統 |
| WO2015067632A1 (en) * | 2013-11-06 | 2015-05-14 | Janssen Sciences Ireland Uc | Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
-
2016
- 2016-05-10 US US15/573,227 patent/US20180353533A1/en not_active Abandoned
- 2016-05-10 CN CN201680040346.1A patent/CN107820423A/zh active Pending
- 2016-05-10 KR KR1020177035145A patent/KR20180004233A/ko not_active Withdrawn
- 2016-05-10 WO PCT/IB2016/000890 patent/WO2016181226A1/en not_active Ceased
- 2016-05-10 AU AU2016259869A patent/AU2016259869A1/en not_active Abandoned
- 2016-05-10 CA CA2983659A patent/CA2983659A1/en not_active Abandoned
- 2016-05-10 HK HK18111254.8A patent/HK1251926A1/zh unknown
- 2016-05-10 JP JP2017559086A patent/JP2018515530A/ja active Pending
- 2016-05-10 RU RU2017142710A patent/RU2017142710A/ru not_active Application Discontinuation
- 2016-05-10 EP EP16753457.7A patent/EP3294268A1/en not_active Withdrawn
- 2016-05-10 MA MA044384A patent/MA44384A/fr unknown
- 2016-05-11 TW TW105114594A patent/TW201705963A/zh unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102439760B1 (ko) | 2021-03-09 | 2022-09-02 | 주식회사 오라팜 | 상기도 감염균 질환 예방 및 치료를 위한 조성물 |
| KR20220126619A (ko) | 2021-03-09 | 2022-09-16 | 주식회사 오라팜 | 급성 호흡기 바이러스 및 로타바이러스 감염 질환 예방 및 치료를 위한 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018515530A (ja) | 2018-06-14 |
| EP3294268A1 (en) | 2018-03-21 |
| CA2983659A1 (en) | 2016-11-17 |
| TW201705963A (zh) | 2017-02-16 |
| CN107820423A (zh) | 2018-03-20 |
| RU2017142710A (ru) | 2019-06-11 |
| US20180353533A1 (en) | 2018-12-13 |
| WO2016181226A1 (en) | 2016-11-17 |
| HK1251926A1 (zh) | 2019-05-03 |
| AU2016259869A1 (en) | 2017-11-30 |
| MA44384A (fr) | 2019-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10485816B2 (en) | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections | |
| JP6629216B2 (ja) | 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 | |
| KR20180004233A (ko) | 상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 | |
| US20200060972A1 (en) | Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections | |
| CN116322681A (zh) | 利拉鲁肽和吉非替尼的抗病毒用途 | |
| HK1228749A1 (en) | Polyinosinic-polycytidylic acid (poly (i:c) formulations for the treatment of upper respiratory tract infections | |
| CN104998250B (zh) | 一种恩替卡韦与甘露聚糖肽药物组合物及其制备方法 | |
| HK1203390B (zh) | 用於治疗上呼吸道感染的聚肌苷酸-聚胞苷酸(聚(i:c))配制品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20171205 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |